Latest Monoclonal antibodies Stories
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
MONROVIA, Calif., Nov. 4, 2014 /PRNewswire/ -- Xencor, Inc.
DALLAS, November 3, 2014 /PRNewswire/ -- According to the new market research report The "Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal
MONROVIA, Calif., Nov. 3, 2014 /PRNewswire/ -- Xencor, Inc.
Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
- A political dynamiter.
More Images (1 images) »